Compare DRH & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRH | AGIO |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | N/A | 2013 |
| Metric | DRH | AGIO |
|---|---|---|
| Price | $9.83 | $30.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $9.81 | ★ $36.63 |
| AVG Volume (30 Days) | ★ 2.7M | 805.6K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $103.08 |
| Revenue Next Year | $2.30 | $126.67 |
| P/E Ratio | $38.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.19 | $22.24 |
| 52 Week High | $10.24 | $46.00 |
| Indicator | DRH | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.48 | 67.90 |
| Support Level | $8.99 | $26.57 |
| Resistance Level | $10.24 | $43.72 |
| Average True Range (ATR) | 0.29 | 1.08 |
| MACD | 0.01 | 0.37 |
| Stochastic Oscillator | 63.89 | 98.44 |
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The revenue is divided between room, food and beverage, and others. The room segment contributes the majority of the revenue. The firm's customers include leisure transients, business transients, and group customers.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.